Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2016 1
2017 2
2018 1
2021 1
2023 3
2024 1
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators. Weber J, et al. N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10. N Engl J Med. 2017. PMID: 28891423 Free article. Clinical Trial.
Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry.
Rob F, Gkalpakiotis S, Kojanová M, Vantuchová Y, Čelakovská J, Horažďovský J, Baláž M, Nečas M, Stuchlík D, Cetkovská P, Hrazdírová K, Machovcová A, Pinková B, Třešňák Hercogová J. Rob F, et al. Among authors: vantuchova y. J Eur Acad Dermatol Venereol. 2025 Dec;39(12):e1056-e1059. doi: 10.1111/jdv.70009. Epub 2025 Aug 13. J Eur Acad Dermatol Venereol. 2025. PMID: 40799158 No abstract available.
Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Flaherty KT, et al. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4. N Engl J Med. 2012. PMID: 22663011 Free article. Clinical Trial.
Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial.
Guttman-Yassky E, Bahadori L, Brooks L, Clark KL, Grindebacke H, Ho CN, Katial R, Pham TH, Walton C, Datto CJ; HILLIER study group†. Guttman-Yassky E, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1211-e1214. doi: 10.1111/jdv.19195. Epub 2023 Jun 12. J Eur Acad Dermatol Venereol. 2023. PMID: 37178404 Clinical Trial. No abstract available.
Brooke-Spiegler syndrome: report of 10 patients from 8 families with novel germline mutations: evidence of diverse somatic mutations in the same patient regardless of tumor type.
Sima R, Vanecek T, Kacerovska D, Trubac P, Cribier B, Rutten A, Vazmitel M, Spagnolo DV, Litvik R, Vantuchova Y, Weyers W, Pearce RL, Pearn J, Michal M, Kazakov DV. Sima R, et al. Among authors: vantuchova y. Diagn Mol Pathol. 2010 Jun;19(2):83-91. doi: 10.1097/PDM.0b013e3181ba2d96. Diagn Mol Pathol. 2010. PMID: 20502185
Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic.
Gkalpakiotis S, Kojanová M, Fialová J, Cetkovská P, Vašků V, Vantuchová Y, Machovcová A, Gkalpakioti P, Hrdá P, Arenberger P. Gkalpakiotis S, et al. Among authors: vantuchova y. Dermatol Ther (Heidelb). 2024 Jan;14(1):115-130. doi: 10.1007/s13555-023-01066-z. Epub 2023 Nov 30. Dermatol Ther (Heidelb). 2024. PMID: 38032433 Free PMC article.
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators. Maio M, et al. Lancet Oncol. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21. Lancet Oncol. 2018. PMID: 29477665 Clinical Trial.
14 results